Cargando…

Surgery in rheumatic and musculoskeletal disease /

"Surgery in Systemic Autoimmune Disease, Volume 15, describes the state-of-the-art of the use of surgery in treating the most common systemic autoimmune diseases (SADS). The volume consists of an introductory chapter concerning the impact of surgery on SADs, follow by eight chapters describing...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Atzeni, Fabiola (Editor ), Masala, Ignazio Francesco (Editor ), Aletaha, Daniel (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Amsterdam, Netherlands : Elsevier, [2018]
Colección:Handbook of systemic autoimmune diseases ; v. 15.
Temas:
Acceso en línea:Texto completo
Texto completo

MARC

LEADER 00000cam a2200000 i 4500
001 SCIDIR_on1029872305
003 OCoLC
005 20231120010250.0
006 m o d
007 cr cnu|||unuuu
008 180330s2018 ne ob 001 0 eng d
040 |a N$T  |b eng  |e rda  |e pn  |c N$T  |d N$T  |d OCLCO  |d EBLCP  |d OPELS  |d OCLCF  |d STF  |d MERER  |d D6H  |d CASUM  |d OCLCQ  |d OCLCO  |d U3W  |d OCLCO  |d LVT  |d OCLCA  |d OCLCQ  |d S2H  |d OCLCO  |d OCLCQ  |d OCLCO  |d K6U  |d OCLCQ  |d OCLCO 
019 |a 1039686281 
020 |a 9780444638885  |q (electronic bk.) 
020 |a 0444638881  |q (electronic bk.) 
020 |z 9780444638878 
020 |z 0444638873 
035 |a (OCoLC)1029872305  |z (OCoLC)1039686281 
050 4 |a RD605.2 
072 7 |a MED  |x 085000  |2 bisacsh 
082 0 4 |a 617.4  |2 23 
245 0 0 |a Surgery in rheumatic and musculoskeletal disease /  |c editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos. 
264 1 |a Amsterdam, Netherlands :  |b Elsevier,  |c [2018] 
264 4 |c �2018 
300 |a 1 online resource 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Handbook of systemic autoimmune diseases ;  |v volume 15 
588 |a Online resource; title from PDF title page (EBSCO, viewed April 3, 2018). 
504 |a Includes bibliographical references and index. 
520 |a "Surgery in Systemic Autoimmune Disease, Volume 15, describes the state-of-the-art of the use of surgery in treating the most common systemic autoimmune diseases (SADS). The volume consists of an introductory chapter concerning the impact of surgery on SADs, follow by eight chapters describing the use of surgery in the treatment of specific diseases in various areas (cardiology, gastroenterology, orthopedics, neurology. etc.) and the possible difficulties and complications. The final five chapters deal with the possible complications arising during the course of biological and non-biological treatment, also providing recommendation concerning their management. International in scope, the list of more than 20 contributors from Europa and America reads like a who's who of clinical researchers in the field. Written by leading international clinical/surgical and scientific experts on surgical problems in SADsProvides a practical guide to the safer use of surgery in patients with autoimmune diseasesIncludes a number of problems and recommendations that cannot be found in other booksDesigned as a 'guide to clinical practice' for surgical interventions required by patients with SADsGives a comprehensive review of the available surgical options"--  |c Provided by publisher 
505 0 |a Front Cover; Surgery in Rheumatic and Musculoskeletal Disease; Handbook of Systemic Autoimmune Diseases; Surgery in Rheumatic and Musculoskeletal Disease; Copyright; Dedication; Contents; List of Contributors; Preface; 1 -- The Spectrum of Rheumatic Diseases; 1. INTRODUCTION; 2. SYSTEMIC AUTOIMMUNE DISEASES; 2.1 Systemic Lupus Erythematosus; 2.2 Rheumatoid Arthritis; 2.3 Systemic Sclerosis; 2.4 Idiopathic Inflammatory Myopathies; 2.5 Antiphospholipid Syndrome; 3. AUTOINFLAMMATORY DISEASES; 4. METABOLIC DISEASES; 4.1 Osteoporosis; 4.2 Crystal Deposition Disease 
505 8 |a 4.2.1 Calcium Pyrophosphate Disease (CPPD)4.3 Gout; 5. DEGENERATIVE DISEASES; 5.1 Osteoarthritis; 6. CONCLUSIONS; KEYPOINTS; REFERENCES; 2 -- Comorbidities in Patients With Rheumatic Disease; 1. INTRODUCTION; 1.1 The Concepts of Comorbidity and Multimorbidity; 1.2 Prevalence of Multimorbidity in Rheumatic Conditions; 2. ASSESSMENT OF COMORBID CONDITIONS; 3. IMPACT OF COMORBIDITIES ON IMPORTANT OUTCOMES; 3.1 Mortality; 3.2 Health Economic Implications; 3.3 Disease-Related Outcomes; 3.4 Outcomes Related to Surgery; 4. DISTINCT COMORBID CONDITIONS; 4.1 Cardiovascular Disease 
505 8 |a 4.2 Pulmonary Disease4.3 Malignancies; 4.4 Gastrointestinal Disease; 4.5 Infections; 4.6 Osteoporosis; 4.7 Depression; 5. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; REFERENCES; 3 -- Drugs Used in Rheumatic Disease; 1. INTRODUCTION; 2. NONSTEROIDAL ANTIINFLAMMATORY DRUGS; 3. GLUCOCORTICOIDS; 4. IMMUNOSUPPRESSANTS/IMMUNOMODULATORS AND DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 4.1 Nonbiological Agents; 4.1.1 Methotrexate; 4.1.2 Leflunomide; 4.1.3 Sulfasalazine; 4.1.4 Antimalarials; 4.1.5 Cyclophosphamide; 4.1.6 Azatihioprine; 4.1.7 Mycophenolate Mofetil 
505 8 |a 4.1.8 Cyclosporine and Tacrolimus4.1.9 Apremilast; 4.1.10 Tofacitinib; 4.2 Biologicals; 4.2.1 Tumor Necrosis Factor-Alpha Inhibitors; 4.2.2 Tocilizumab; 4.2.3 Anakinra, Canakinumab, and Rilonacept; 4.2.4 Rituximab; 4.2.5 Abatacept; 4.2.6 Secukinumab; 4.2.7 Ustekinumab; 4.2.8 Belimumab; 5. COLCHICINE; 6. URATE-LOWERING AGENTS; 7. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; DEDICATION; REFERENCES; 4 -- Essential and Optional Drugs for Rheumatic Diseases; 1. RHEUMATOID ARTHRITIS AND SPONDYLARTHRITIDES; 2. GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA; 3. VASCULITIDES 
505 8 |a 4. CONNECTIVE TISSUE DISEASES5. BASIC LABORATORY ASSESSMENT; 6. GLUCOCORTICOIDS; 7. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; 8. DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 9. ANTIMALARIALS; 10. CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 10.1 Methotrexate; 10.2 Sulfasalazine; 10.3 Leflunomide; 11. BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 11.1 Tumor Necrosis Factor Blockers (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab); 11.2 Interleukin-1 (Receptor) Blockade (Anakinra, Canakinumab); 11.3 Interleukin-6 (Receptor) Blockade (Sarilumab, Tocilizumab) 
650 0 |a Autoimmune diseases  |x Surgery. 
650 0 |a Rheumatism  |x Surgery. 
650 0 |a Musculoskeletal system  |x Diseases  |x Surgery. 
650 0 |a Musculoskeletal system  |x Diseases. 
650 1 2 |a Autoimmune Diseases  |x surgery  |0 (DNLM)D001327Q000601 
650 2 2 |a Musculoskeletal Diseases  |x surgery  |0 (DNLM)D009140Q000601 
650 2 |a Musculoskeletal Diseases  |0 (DNLM)D009140 
650 6 |a Maladies auto-immunes  |0 (CaQQLa)201-0064242  |x Chirurgie.  |0 (CaQQLa)201-0379972 
650 6 |a Rhumatisme  |0 (CaQQLa)201-0006739  |x Chirurgie.  |0 (CaQQLa)201-0379972 
650 6 |a Appareil locomoteur  |x Maladies.  |0 (CaQQLa)201-0050155 
650 7 |a MEDICAL  |x Surgery  |x General.  |2 bisacsh 
650 7 |a Rheumatism  |x Surgery  |2 fast  |0 (OCoLC)fst01097024 
655 4 |a Internet Resources. 
655 4 |a Charts. 
700 1 |a Atzeni, Fabiola,  |e editor. 
700 1 |a Masala, Ignazio Francesco,  |e editor. 
700 1 |a Aletaha, Daniel,  |e editor. 
830 0 |a Handbook of systemic autoimmune diseases ;  |v v. 15. 
856 4 0 |u https://sciencedirect.uam.elogim.com/science/handbooks/15715078/15  |z Texto completo 
856 4 0 |u https://sciencedirect.uam.elogim.com/handbook/handbook-of-systemic-autoimmune-diseases/vol/15/suppl/C  |z Texto completo